Principal Investigators: Ole-Bjørn Tysnes, Charalampos Tzoulis

To test the potential of NR as a neuroprotective therapy for ALS, we will perform NO-ALS, a multi-centre, phase II randomized double-blinded clinical trial, comparing combined oral NR and pterostilbene to placebo in early ALS. Based on power estimations, a total of 180 patients will be recruited nation-wide.

This project is entirely novel and has the potential to discover a therapy modulating disease activity and progression in ALS, thus vastly improving patient care and prognosis.

We started including patients in October 2020.

Newsletter 1
Newsletter 2
Newsletter 3
Newsletter 4
Newsletter 5
Newsletter 6
Newsletter 7
Newsletter 8
Newsletter 9
Newsletter 10
Newsletter 11
Newsletter 12
Newsletter 13
Newsletter 14
Newsletter 15
Newsletter 16